Crestline Management LP Makes New $332,000 Investment in Penumbra, Inc. (NYSE:PEN)

Crestline Management LP acquired a new stake in Penumbra, Inc. (NYSE:PEN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,400 shares of the company’s stock, valued at approximately $332,000.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. lifted its holdings in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new position in shares of Penumbra during the fourth quarter valued at approximately $56,000. Huntington National Bank lifted its stake in shares of Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after buying an additional 154 shares during the period. Mather Group LLC. grew its stake in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after acquiring an additional 208 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Transactions at Penumbra

In other news, CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares of the company’s stock, valued at approximately $4,359,498. The trade was a 11.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the sale, the executive vice president now owns 66,539 shares in the company, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 159,096 shares of company stock valued at $44,959,983. Insiders own 5.00% of the company’s stock.

Penumbra Price Performance

PEN stock opened at $297.25 on Friday. The stock has a 50-day simple moving average of $277.75 and a 200-day simple moving average of $260.95. The firm has a market cap of $11.51 billion, a P/E ratio of 874.26, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. During the same quarter in the prior year, the business posted $0.41 earnings per share. Penumbra’s revenue for the quarter was up 16.3% on a year-over-year basis. On average, equities analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

PEN has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. UBS Group restated a “buy” rating and issued a $330.00 price target (up previously from $320.00) on shares of Penumbra in a report on Thursday, April 24th. StockNews.com upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a report on Thursday, April 24th. Canaccord Genuity Group boosted their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. increased their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.